The use of targeted drug crizotinib for lung adenocarcinoma

Crizotinib is mainly suitable for patients with non-small cell lung cancer (NSCLC) with specific genetic mutations, including ALK fusion mutation-positive and ROS1 rearrangement-positive patients. Crizotinib may be an effective treatment option for patients with lung adenocarcinoma who have ALK fusion mutations or ROS1 rearrangements in their tumor tissue.

Multiple clinical studies have shown that crizotinib has demonstrated significant efficacy in the treatment of ALK-positive or ROS1-positive lung adenocarcinoma patients. It can significantly extend patients' progression-free survival (PFS) and overall survival (OS), while reducing patients' symptoms and improving their quality of life. However, it should be noted that the efficacy of crizotinib may vary depending on individual differences, disease severity, and the presence of other genetic mutations.

Crizotinib is usually administered orally, and the recommended dose is 2 times a day, 250mg each time, that is, the total daily dose is 500mg. Patients should take it on time and in the right amount under the guidance of a doctor, and follow the doctor's medication instructions.

Some adverse reactions may occur during the use of crizotinib, including nausea, vomiting, diarrhea, rash, visual impairment, abnormal liver function, and interstitial lung disease. The severity and frequency of these adverse reactions vary among individuals. Therefore, patients should closely monitor their physical condition during medication and promptly report any discomfort to their doctor.

Before using crizotinib, patients should undergo genetic testing to confirm whether there are indications such as ALK fusion mutations or ROS1 rearrangements.

Patients should strictly follow the doctor's instructions when taking medication and are not allowed to change the dosage or stop medication without authorization. During the medication period, patients should regularly undergo laboratory tests such as liver and kidney function to monitor their physical condition. In the event of serious adverse reactions or disease progression, patients should seek medical treatment promptly and follow the doctor's recommendations for treatment.